Exchange: NASDAQ·Updated 07:30 PM EDT
ANAB logo

ANAB AnaptysBio Inc

$56.28
$1.01
(1.76%)
Today
Closed $56.28
$0.00
(0.00%)
After Hours
EarningsAug 31
Mkt Cap$1.67B
Vol358,569.00

About ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
47

Neutral Sentiment

How do you feel about ANAB?

Advertisement|Remove ads.